Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study

Blood (2024) 144 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2024-200936

Published: 2024

Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 224–227.

https://doi.org/10.1182/blood-2022-160338

Published: 2022

Journal Articles

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda

Blood (2021) 138 (Supplement 1): 68.

https://doi.org/10.1182/blood-2021-144544

Published: 2021

Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134446

Published: 2020

Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood (2019) 134 (Supplement_1): 35.

https://doi.org/10.1182/blood-2019-121424

Published: 2019

Journal Articles

Increasing Cross-Referral and Recruitment to Clinical Trials: A New Approach

Roslyn Ristuccia, BSc MMedSc, Xavier C Badoux, MBBS, Melinda Gibson, BAppS MHSc, Admir Huseincehajic, BSc, Judith Trotman, MBChB

Blood (2015) 126 (23): 636.

https://doi.org/10.1182/blood.V126.23.636.636

Published: 2015

Journal Articles

Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)

Sarit Assouline, MD MSc, Valeria Buccheri, MD PhD, Alain Delmer, MD, Gianluca Gaidano, MD PhD, Michael Brewster, BSc, Olivier Catalani, Sai Li, MD PhD, Christine McIntyre, PhD, Pakeeza Sayyed, PhD, Xavier C Badoux, MBBS

Blood (2014) 124 (21): 1995.

https://doi.org/10.1182/blood.V124.21.1995.1995

Published: 2014

Journal Articles

Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL)

Xavier C Badoux, MB BS, Giles Best, BSc (Hons), PhD, Sara Gabrielli, Miss, Melanie Hayes, PhD, Ying Zhu, PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Bryone J Kuss, MBBS, PhD FRCPA, FRACP

Blood (2014) 124 (21): 1959.

https://doi.org/10.1182/blood.V124.21.1959.1959

Published: 2014

Journal Articles

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C. Badoux, Steliana Calin, James M. Reuben, Susan O’Brien, Steven M. Kornblau, Hagop M. Kantarjian, Hui Gao, Alessandra Ferrajoli

Blood (2013) 122 (5): 734–737.

https://doi.org/10.1182/blood-2013-04-495341

Published: 2013

Journal Articles

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Paolo Strati, Michael J. Keating, MD, William G. Wierda, MD, PhD, Xavier C. Badoux, MBBS, Steliana Calin, MD, James M. Reuben, PhD, Susan M. O'Brien, MD, Steven M. Kornblau, MD, Hagop M. Kantarjian, MD, Bang-Ning Lee, PhD, PA-C, Alessandra Ferrajoli, M.D.

Blood (2012) 120 (21): 3932.

https://doi.org/10.1182/blood.V120.21.3932.3932

Published: 2012

Journal Articles

Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Xavier C Badoux, MBBS, Michael J Keating, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Stefan Faderl, MD, Zeev Estrov, Manolo Pasia, BSN, Susan Lerner, MS, BA, Rachel L Sargent, MD, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD

Blood (2011) 118 (21): 980.

https://doi.org/10.1182/blood.V118.21.980.980

Published: 2011

Journal Articles

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

Xavier C. Badoux, Michael J. Keating, Sijin Wen, Bang-Ning Lee, Mariela Sivina, James Reuben, William G. Wierda, Susan M. O'Brien, Stefan Faderl, Steven M. Kornblau, Jan A. Burger, Alessandra Ferrajoli

Blood (2011) 118 (13): 3489–3498.

https://doi.org/10.1182/blood-2011-03-339077

Published: 2011

Includes: Supplemental data

Journal Articles

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

Xavier C. Badoux, Michael J. Keating, Xuemei Wang, Susan M. O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian, William G. Wierda

Blood (2011) 118 (8): 2085–2093.

https://doi.org/10.1182/blood-2011-03-341032

Published: 2011

Includes: Supplemental data

Journal Articles

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

Xavier C. Badoux, Michael J. Keating, Xuemei Wang, Susan M. O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian, William G. Wierda

Blood (2011) 117 (11): 3016–3024.

https://doi.org/10.1182/blood-2010-08-304683

Published: 2011

Includes: Supplemental data

Journal Articles

Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3.

Xavier C. Badoux, MBBS, Carlos Bueso Ramos, MD, PhD, David Harris, B.S., Ping Li, Ph.D., Zhiming Liu, B.S., Jan Burger, M.D., Susan O'Brien, MD, Alessandra Ferrajoli, MD., Michael Keating, MD, Zeev Estrov, MD

Blood (2009) 114 (22): 1242.

https://doi.org/10.1182/blood.V114.22.1242.1242

Published: 2009

Journal Articles

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Xavier C. Badoux, MBBS, Michael Keating, MD, Susan O'Brien, MD, Tapan Kadia, MD, Alessandra Ferrajoli, MD., Stefan Faderl, MD, Charles Koller, MD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD, PhD, William G. Wierda, M.D., Ph.D,

Blood (2009) 114 (22): 3431.

https://doi.org/10.1182/blood.V114.22.3431.3431

Published: 2009

Journal Articles

Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).

Nicolas Batty, MD, Xavier C. Badoux, MBBS, Michael Keating, MD, E. Lin, Susan Lerner, M.S., RHIA, Susan O'Brien, Alessandra Ferrajoli, MD., Tapan Kadia, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 3448.

https://doi.org/10.1182/blood.V114.22.3448.3448

Published: 2009

Journal Articles

Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.

Xavier C. Badoux, MBBS, Michael Keating, MD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Lynne V Abruzzo, MD, PhD, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 1248.

https://doi.org/10.1182/blood.V114.22.1248.1248

Published: 2009

Journal Articles

Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Alessandra Ferrajoli, MD, Xavier C. Badoux, MBBS, Susan O'Brien, MD, William G. Wierda, MD, PhD, Stefan Faderl, MD, Zeev Estrov, MD, Manolo Pasia, RN, Bang-Ning Lee, PhD, James M. Reuben, PhD, Hagop Kantarjian, MD, Michael Keating, MD

Blood (2009) 114 (22): 206.

https://doi.org/10.1182/blood.V114.22.206.206

Published: 2009

NARROW

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Increasing Cross-Referral and Recruitment to Clinical Trials: A New Approach

Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL)

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3.

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).

Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.

Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only